Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)
Authors
Henao-Restrepo, AMCamacho, A
Longini, IM
Watson, CH
Edmunds, WJ
Egger, M
Carroll, MW
Dean, NE
Diatta, I
Doumbia, M
Draguez, B
Duraffour, S
Enwere, G
Grais, R
Gunther, S
Gsell, PS
Hossmann, S
Watle, SV
Kondé, MK
Kéïta, S
Kone, S
Kuisma, E
Levine, MM
Mandal, S
Mauget, T
Norheim, G
Riveros, X
Soumah, A
Trelle, S
Vicari, AS
Røttingen, JA
Kieny, MP
Issue Date
2016-12-23Submitted date
2017-01-11
Metadata
Show full item recordJournal
Lancet (London, England)Abstract
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.Publisher
ElsevierPubMed ID
28017403Language
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(16)32621-6